The authors provide a review of the oncogenic role of the most relevant molecular alterations in NSCLC and emerging treatments in this setting beyond epidermal growth factor receptor (EGFR)-driven and anaplastic lymphoma kinase (ALK)-driven diseases.
[Cancer]
